Compare Open Text Corporation (OTEX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Open Text Corporation vs Sana Biotechnology Inc — how do they compare? Open Text Corporation trades at $23.7 (market cap $5.61B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Open Text Corporation is far larger — about 6.7× Sana Biotechnology Inc's market cap, and Open Text Corporation pays a 4.82% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Open Text Corporation for 23 Days and Sana Biotechnology Inc for 23 Days on average.
| OTEX | SANA | |
|---|---|---|
Market Cap | $5.61B | $836.71M |
Volume | 1,197,475 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $39.69 | $5.92 |
52-Week Low | $20.01 | $2.68 |
Typical Hold Time | 23 Days | 23 Days |
Enterprise Value | $10.63B | $749.96M |
Dividend Yield | 4.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OpenText (OTEX) trades at $23.595, up 1.97% today, showing strong earnings momentum with three consecutive quarterly beats. The stock trades at discounted valuations (P/E 9.01, P/S 1.1) compared to sector peers. Recent corporate actions include a $1 billion senior secured notes offering and strategic AI partnership with Cohere, while technical indicators signal near-term bearish pressure with RSI at overbought levels.
The investment case balances attractive fundamentals against technical headwinds. Strong cloud growth (22.5% bookings growth in fiscal 2026) and improving margins support upside to the $28.30 consensus target, but high debt levels and bearish technical signals warrant caution. The stock offers value opportunity for patient investors despite near-term volatility.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
